Home / Compare
14 head-to-heads · provider and drug level · statuses everywhere
Head-to-head comparisons that name their evidence
Every comparison below states what's operator-supplied, what's reported, and what's verified — including the five where our partner NexLife appears, which carry the disclosure up top and the same standards throughout. The drug-level pages (Foundayo's two duels) answer the questions the 2026 approvals created; the provider pages answer the ones your budget does.
Same drug, two labels — and the label decides your insurance, your programs, and your price.
Read the head-to-head →SURMOUNT-5 settled efficacy; SELECT answers with a heart. The brand duel, sorted by patient.
Read the head-to-head →The diabetes head-to-head where weight is the tiebreaker — and the weight-only reader's exit ramp.
Read the head-to-head →Flat-rate claim vs flat-plus-disputed-membership: the budget-tier structure fight.
Read the head-to-head →Cash floor vs insurance machinery — different products for different wallets.
Read the head-to-head →Operator-supplied injectable floor vs the cheapest reported tablet bundle.
Read the head-to-head →A published ladder against a thin-documentation budget name.
Read the head-to-head →The $139 twins — which claim has more structure to hold accountable.
Read the head-to-head →The cheapest reported duo, each with its asterisk in a different place.
Read the head-to-head →Footprint as a product vs structure with one disputed number.
Read the head-to-head →Lilly's pill against Lilly's injectable: the seven-point trade.
Read the head-to-head →The two real GLP-1 pills: flat price versus free schedule.
Read the head-to-head →